Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.

  • Dias M
  • McKinnon R
  • Sorich M
  • Readers

    Mendeley users who have this article in their library.
  • Citations

    Citations of this article.

Abstract

AIM Pre-emptive irinotecan dose reduction for UGT1A1*28 homozygotes may result in reduced risk of severe neutropenia and diarrhea. However, clinical utility and cost-effectiveness are dependent upon such a dose reduction not impacting irinotecan efficacy. Whether UGT1A1*28 genotype is associated with irinotecan response therefore is an important gap in existing knowledge to inform clinical utility. MATERIALS & METHODS A systematic review and meta-analysis was performed to analyze the difference in objective response rate (ORR) between irinotecan-administered cancer patients with different UGT1A1*28 genotypes: *28/*28 (homozygous variant), *1/*28 (heterozygous variant) or *1/*1 (wild-type). The effect of irinotecan dose on the association between UGT1A1*28 and ORR was also assessed. RESULTS Differences in ORR for either of the genotype comparisons, *28/*28 versus *1/*1 and *1/*28 versus *1/*1, were not statistically significant. Irinotecan dose also did not impact upon ORR differences between UGT1A1 genotype groups. CONCLUSION An individual's response to irinotecan is unlikely to be affected by UGT1A1*28 status.

Author-supplied keywords

  • 1 inhibitor com-
  • 28
  • a range of cancers
  • irinotecan is a topoisomerase
  • irinotecan n meta-ana
  • lysis n pharmacogenetics n
  • monly used to treat
  • particu-
  • response n ugt1a1

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Mafalda M Dias

  • Ross A McKinnon

  • Michael J Sorich

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free